AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
crinecerfont 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| corticotropin-releasing factor (CRF) receptor antagonists | 5844 | None |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Crinecerfont is a selective corticotropin-releasing factor (CRF) type 1 receptor antagonist. Crinecerfont blocks the binding of CRF to CRF type 1 receptors in the pituitary but not CRF type 2 receptors. Crinecerfont binding to CRF type 1 receptors inhibits adrenocorticotropic hormone (ACTH) secretion from the pituitary, thereby reducing ACTH-mediated adrenal androgen production.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 13, 2024 | FDA | Neurocrine Biosciences |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA EPC | N0000194151 | Corticotropin-releasing Factor Type 1 Receptor Antagonist |
| FDA MoA | N0000194152 | Corticotropin-releasing Factor Type 1 Receptor Antagonists |
| CHEBI has role | CHEBI:35469 | antidepressant |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Congenital adrenal hyperplasia | indication | 237751000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 10905690 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11311544 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11730739 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 10905690 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11311544 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11730739 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 10905690 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11311544 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 11730739 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | 10905690 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | 11311544 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | 11730739 | Jan. 21, 2035 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 12128033 | June 9, 2041 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 12128033 | June 9, 2041 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | 12128033 | June 9, 2041 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | 12128033 | June 9, 2041 | ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2029 | NEW CHEMICAL ENTITY |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2029 | NEW CHEMICAL ENTITY |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2029 | NEW CHEMICAL ENTITY |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | Dec. 13, 2029 | NEW CHEMICAL ENTITY |
| 100MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2031 | ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 25MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2031 | ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG | CRENESSITY | NEUROCRINE | N218808 | Dec. 13, 2024 | RX | CAPSULE | ORAL | Dec. 13, 2031 | ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
| 50MG/ML | CRENESSITY | NEUROCRINE | N218820 | Dec. 13, 2024 | RX | SOLUTION | ORAL | Dec. 13, 2031 | ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Corticotropin-releasing factor receptor 1 | GPCR | ANTAGONIST | IC50 | 8.40 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 752253-39-7 | SECONDARY_CAS_RN |
| CHEMBL291657 | ChEMBL_ID |
| C000723083 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4043642 | VANDF |
| C5420921 | UMLSCUI |
| CHEBI:34969 | CHEBI |
| 10958 | INN_ID |
| 5282340 | PUBCHEM_CID |
| 3533 | IUPHAR_LIGAND_ID |
| MFT24BX55I | UNII |
| 2701386 | RXNORM |
| C502407 | MESH_SUPPLEMENTAL_RECORD_UI |
| D12366 | KEGG_DRUG |
| 391363 | MMSL |
| 43591 | MMSL |
| d10238 | MMSL |
| 019945 | NDDF |
| MFT24BX55I | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Crenessity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-5025 | CAPSULE | 25 mg | ORAL | NDA | 29 sections |
| Crenessity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-5050 | CAPSULE | 50 mg | ORAL | NDA | 29 sections |
| Crenessity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-5100 | CAPSULE | 100 mg | ORAL | NDA | 29 sections |
| Crenessity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-5250 | SOLUTION | 50 mg | ORAL | NDA | 29 sections |